International Journal of Clinical Research

Objective To explore the efficacy and safety of high-dose and standard-dose glucocorticoids in the treatment of sudden deafness using the method of meta-analysis. Methods The relevant literature published in China from 2000 to 2024 on different high-dose systemic glucocorticoids for the treatment of sudden deafness was systematically retrieved using keywords in databases such as CNKI and VIP. Literature was screened according to the pre-established inclusion and exclusion criteria, and the RevMan5.4.1 software package was used to perform a meta-analysis on studies that met the quality standards. Results Four randomized controlled studies with a total of 462 patients were included. Meta-analysis showed that there was a statistically significant difference in the total effective rate between high-dose and standard-dose systemic glucocorticoids for the treatment of sudden deafness (RR=1.39, 95%CI=1.13-1.69, P=0.001); there was no statistical difference in the cure rate (RR=1.50, 95%CI=0.89-2.55, P=0.13). Adverse drug reactions mainly included digestive system reactions, increased blood sugar, insomnia, liver and kidney damage, etc. There was no statistically significant difference in adverse reactions between the two groups (RR=1.02, 95%CI=0.76-1.37, P=0.88). Conclusion 1. High-dose glucocorticoids have a higher efficacy in the treatment of sudden deafness than standard-dose glucocorticoids, but there is no significant difference in the cure rate, which requires further research and discussion. 2. There is no significant difference in the incidence of adverse reactions between high-dose and standard-dose glucocorticoids in the treatment of sudden deafness.

Sudden deafness; Glucocorticoids; High-dose; Randomized controlled; Meta-analysis